OmniAb, Inc.

OmniAb, Inc. creates and licenses antibody discovery technologies to pharmaceutical and biotechnology companies and academic research institutions. Its platform incorporates genetically engineered transgenic animals—including rats, mice, chickens, and cow-inspired models—to produce diverse, naturally optimized antibody repertoires with human genetic sequences. These proprietary animals are complemented by computational antigen design, microfluidic and microcapillary single B cell screening platforms, and artificial intelligence-driven bioinformatics suites for data analysis and hit optimization. Together, these technologies support the discovery of diverse therapeutic modalities such as monoclonal and bispecific antibodies, single-domain antibodies, and antibody-drug conjugates.

As of December 31, 2025, the company collaborated with 107 active partners supporting 407 active programs across diverse geographic regions and therapeutic areas. These partnered programs included 27 antibodies in active clinical development, two candidates under regulatory review, and three commercialized products. The provided text contains no statements regarding the company's founding year, website address, or headquarters location.

Summary of the business section of OmniAb's latest annual report, written by StockData.

“As of December 31, 2025, we had 107 active partners with 407 active programs using the OmniAb technology platform, including 27 OmniAb-derived antibodies in clinical development by our partners, two under regulatory review, and three approved products developed and commercialized by our partners.”